

Movilización de ácido araquidónico por estímulos de la respuesta inmune innata

Alma M. Astudillo, Gema Pérez-Chacón, María A. Balboa & Jesús Balsinde

*Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC),
47003 Valladolid, Spain*

December 3, 2009

Resumen - Las células del sistema inmune innato pueden reconocer patógenos mediante una serie de receptores extracelulares e intracelulares, tales como los receptores para Fc, receptores de manosa y receptores tipo Toll. El reconocimiento de estos patógenos conduce a la síntesis de mediadores lipídicos de la inflamación conocidos bajo el nombre colectivo de eicosanoides. Los eicosanoides derivan del ácido araquidónico (AA), un ácido graso ω -6 poliinsaturado que los mamíferos pueden incorporar directamente a través la dieta o sintetizar a partir de ácido linoleico. El AA no se halla nunca en forma libre, sino esterificando la posición sn-2 de los glicerofosfolípidos de membrana. Por ello, antes de que se produzca la síntesis de eicosanoides, el AA tiene que ser liberado de los fosfolípidos. Las enzimas involucradas en tal liberación son las fosfolipasas A_2 (PLA_2). Aunque las rutas de señalización que median la producción de eicosanoides por células involucradas en inmunidad innata no están bien caracterizadas, se ha demostrado de modo concluyente que la fosfolipasa A_2 citosólica de grupo IVA ($cPLA_2\alpha$) es una enzima fundamental en este proceso y que, dependiendo del tipo celular y de las condiciones de estimulación, existen mecanismos reguladores de cross-talk entre la $cPLA_2\alpha$ y otras enzimas con actividad PLA_2 presentes en las células.

Palabras clave - Ácido araquidónico; receptores de la respuesta inmune innata; fosfolipasa A_2 citosólica dependiente de Ca^{2+} ; fosfolipasa A_2 secretada.

ARACHIDONIC ACID MOBILIZATION BY STIMULI OF THE INNATE IMMUNE RESPONSE

Summary - Cells of the innate immune system can recognize pathogens via a number of extracellular and intracellular receptors, such as Fc, mannose or Toll-like receptors. Recognition of these pathogens leads to the synthesis of inflammatory lipid mediators, the eicosanoids. The eicosanoids derive from arachidonic acid (AA), an ω -6 polyunsaturated fatty acid that mammals can incorporate directly through dietary sources or synthesize from linoleic acid. In cells, AA seldom occurs in free fatty acid form, and is almost always found esterified at the sn-2 position of glycerophospholipids. Thus, it has to be removed from there before any eicosanoid synthesis can occur. The enzymes involved in such a removal are the phospholipase A_2 s (PLA_2 s). The signaling pathways that mediate the production of eicosanoids by cells involved in innate immunity are not completely understood, but it is now clear that the calcium-dependent cytosolic group IVA PLA_2 ($cPLA_2\alpha$) is a critical enzyme in this process, and that, depending on cell type and stimulation conditions, regulatory cross-talk mechanisms exist between $cPLA_2\alpha$ and other PLA_2 enzymes present in the cells.

Keywords - Arachidonic acid; innate immune response receptors; Ca^{2+} -dependent cytosolic phospholipase A_2 ; secreted phospholipase A_2 .

1. Introduction

The phospholipase A_2 s (PLA_2 s) are enzymes that catalyze the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, generating a free fatty acid and a lysophospholipid. This reaction constitutes the major pathway through which arachidonic acid (AA) is released from glycerophospholipids during cellular

stimulation. Free AA is the precursor of the eicosanoids, which include the prostaglandins, generated through cyclooxygenase-catalyzed reactions, and the leukotrienes and lipoxins, generated through lipoxygenase-catalyzed reactions [1]. Additionally, the PLA₂ reaction generates a platelet-activating factor (PAF) precursor when the lysophospholipid product possesses a choline headgroup and an alkyl linkage at the sn-1 position. Thus, PLA₂s are important signaling enzymes which regulate the generation of lipid second messengers of different types with key roles in regulating innate immune responses. In turn, direct inhibition of PLA₂ would have the potential of blocking multiple kinds of lipid-signaling pathways at once, which could be of therapeutic advantage in certain settings. Targeting and inhibiting the PLA₂ reaction has proved problematic since numerous PLA₂ enzymes exist in cells with overlapping activation properties. Only in human, at least 22 proteins possessing PLA₂ activity have been described [2, 3]. Thus the first step for a rational PLA₂ drug design strategy should be to define the involvement of the different PLA₂ classes present in cells and elucidate their roles in lipid mediator biosynthesis during signaling triggered by multiple innate immunity receptors.

2. Phospholipase A₂

The PLA₂ enzymes have systematically been classified into several group types according to their primary structure [3, 4]. The latest update to this classification, published in 2009 [2] included fourteen groups, most of them with several sub-groups. Only PLA₂s whose nucleotide sequence has been determined should be included in the classification. From a mechanistic point of view, the PLA₂s can be grouped into two major families, namely the low-molecular mass enzymes (>20 kDa), which utilize a catalytic histidine, and the high molecular mass enzymes (<40 kDa), which utilize a catalytic serine [4,5]. For a detailed information on the biochemistry and function of PLA₂ enzymes, the reader is kindly referred to recent reviews on the subject [2-8].

From the point of view of cellular regulation, mammalian PLA₂ enzymes involved in AA metabolism are frequently classified into three families, namely the Ca²⁺-dependent cytosolic PLA₂s (cPLA₂s), the Ca²⁺-dependent secreted PLA₂ (sPLA₂s), and the Ca²⁺-independent cytosolic PLA₂s (iPLA₂s) [5,7]. Of these families, the first two have been repeatedly implicated in AA mobilization in response to a variety of

immunoinflammatory stimuli. Today, it is firmly established that the calcium-dependent cytosolic group IVA PLA₂α (cPLA₂α) is the critical enzyme in AA release (Figure 1) [9, 10] and that, depending on cell type and stimulation conditions, a secreted PLA₂ –in particular, that belonging to groups IIA, V, and X– may also participate by amplifying the cPLA₂α-regulated response [11-15]. There is no compelling evidence that iPLA₂ enzymes play an effector role in AA mobilization in response to stimuli of the innate immune response [5], but these enzymes may participate in the formation of cellular AA pools by regulating basal AA reacylation reactions [16-18].

A number of agents that exert effects on cells via innate immune receptors elicits a series of signals that ultimately lead to increased PLA₂ activity. Elucidation of these signals has been the subject of much effort for the last twenty years. Figure 2 shows the PLA₂ signal transduction mechanism developed over the years for major immunoinflammatory cells such as macrophages and mast cells. The model depicted in Fig 2 contemplates a scenario where the concerted action of two distinct PLA₂s leads to a full AA release response. cPLA₂α appears to be responsible for the bulk of the AA release, whereas the sPLA₂ effects the AA release as well, but may primarily act to amplify the response by providing additional signals for full activation of the cPLA₂α. The cells respond to two different kinds of signals that generate either immediate (min) or delayed responses (h). In the first case, the agonist acts on pre-existing proteins, whereas in the latter, synthesis of new protein effectors is a key event. In either case, the foremost event is the translocation and activation of cPLA₂α in an intracellular compartment. The mechanism of activation of this enzyme has been the subject of many studies, and generally involves the concerted action of the mitogen-activated protein kinase (MAPK) cascade and transient elevations of the intracellular Ca²⁺ concentration [7-10]. Examples have been provided to indicate that cPLA₂ activation may also take place in the absence of intracellular Ca²⁺ elevations [19-21].

Activation of cPLA₂α may precede or follow the activation of a sPLA₂ which, depending on cellular type, may belong to groups IIA, V, or X. Depending on stimulation conditions, the cPLA₂α-modulation of sPLA₂ cellular activity may occur at a gene regulatory level (delayed responses) or at the level of regulation of enzyme activity itself (immediate responses). In the

latter case, a variety of cellular mechanisms may account for this activation, from rearrangement of membrane phospholipids that enables further PLA₂ attack, to more sophisticated biochemical mechanisms such as inactivation of endogenous inhibitors or Ca²⁺ fluxes. The situation is further complicated by the evidence that the sPLA₂ may also act to regulate cPLA₂α by various mechanisms, including the regulation of phosphorylation reactions. Specific examples are provided in the following sections.

While it is clear that cPLA₂α acts predominantly on perinuclear membranes, the precise site of action of the sPLA₂ has been the subject of numerous studies. The enzyme appears to be released to the extracellular medium, from which it re-associates with the outer cellular surface where it hydrolyzes phospholipids. However recent studies have suggested that the enzyme is re-internalized deep into the cell, probably via the caveolae system to the vicinity of nuclear membranes [22, 23]. Whether the enzyme is still active in the cellular interior or this represents a signal termination mechanism is unclear at present. This is currently an area of active study. Recent data have suggested that sPLA₂ acts intracellularly just prior secretion of the enzyme to the extracellular medium [24, 25].

3. Receptors of the innate immune response

The immune system can be divided into two categories: the innate or non-specific immunity and the adaptive or specific immunity. The latter is based on lymphoid cell-surface receptors generated by gene rearrangements that undergo somatic hypermutations in order to recognize an infinite variety of antigens. This response is more complex than the innate response, as the antigen has to be processed first. The innate or non-specific immunity is present in almost all multicellular organisms and constitutes the first line of defense against invading pathogens.

The innate immune response system has the capacity to directly recognize a broad range of pathogens using a repertoire of receptors, the so-called pathogen recognition receptors (PRRs) [26]. These receptors are encoded in the germ line of each individual and do not undergo somatic mutations, as is the case of the receptors of adaptive immunity. PRRs recognize conserved molecular patterns of foreign organisms such as viruses, bacteria, fungi and parasites, which are

denominated pathogen-associated molecular patterns (PAMPs), although they are present on both pathogenic and non-pathogenic microorganisms. They comprise sugars, proteins and lipids, as well as distinct nucleic acid motifs. There are several hundred of these PAMPs, that directly activate immune cells, triggering a signaling cascade that lead to the expression of a variety of genes involved in the inflammatory and immune responses.

Among the PRRs, the best characterized are the TLRs [27-32] (Figure 3). Up to date, thirteen TLRs have been described in mice and human, TLR10 being expressed exclusively in human and TLR11-13 in mice [33]. In humans, the TLRs can be sub-divided into five subfamilies based on amino acid sequences, namely TLR2 (including TLR1, TLR2, TLR6 and TLR10), TLR3, TLR4, TLR5 and TLR9 (including TLR7, TLR8 and TLR9) [34]. In mice, TLR11, 12 and 13 comprise another additional subfamily [35]. The TLR3 and TLR9 families are located exclusively in endosomal compartments and are considered intracellular receptors [36].

Other types of PRRs include (i) CD14, co-receptor for bacterial LPS [37], (ii) C-type lectin receptors (CLRs) such as the mannose receptor or CD206 [38], dectin-1, the primary macrophage receptor for the phagocytosis of yeast [39], or DC-SIGN [40]; (iii) scavenger receptors (SRs), a group of receptors involved in receptor-mediated endocytosis of polyanionic ligands such as low density lipoproteins (LDL) modified by oxidation or acetylation [41]; (iv) the formyl-methionyl-leucyl-phenylalanine (fMLP) receptor, mainly present in neutrophils [42]; and (v) a series of intracellular receptors such as the nucleotide oligomerization domain (NOD)-like receptors (NLRs) [43] or the RIG-I-like helicases (RLHs) [36,44].

On the other hand, the innate immune system also includes a series of receptors that do not directly recognize the pathogens, but do it so when the pathogens are coated with opsonins. These are the complement receptor type 3 (CR3 or CD11b/CD18), and the Fc receptors (FcRs), and are generally considered the link between innate and adaptive immunities [45,46]. CR3 is the main receptor mediating type II phagocytosis of complement-coated particles, but it has been also implicated in nonopsonic phagocytosis of zymosan and *Mycobacterium kansasii* through engagement to distinct sites [47]. Thus, in a general sense CR3 could also be considered a PRR.

4. TLRs and AA mobilization

TLR2 - Little information is available on TLR2-mediated stimulation of PLA₂ leading to AA mobilization. Suram et al. [48] showed that, in RAW264.7 macrophages, TLR2 acts together with dectin-1 to activating cPLA₂α and cyclooxygenase-2 expression upon stimulation with soluble lipopeptide-2 (MALP-2) and particulate β-glucan (P-βG), respectively. In bone marrow-derived mast cells of sPLA₂-V-null mice stimulated with the TLR2 agonist Pam3CSK4, the release of AA and the production of leukotriene C₄ and prostaglandin D₂ were diminished, as well as the phosphorylation of ERK1/2 and cPLA₂α, demonstrating a role of endogenous group V sPLA₂ in TLR2-mediated stimulation through the activation of ERK and cPLA₂α [49]. Activation of cPLA₂α via MAPK, with enhancement of AA release in mouse peritoneal macrophages, COX-2 induction and eicosanoid production through stimulation of TLR2 with the bacteria *Listeria monocytogenes* has also been reported [50].

TLR3 - Pindado et al. [51] studied the mechanism of activation of TLR3 with viral dsRNA in RAW264.7 macrophages. dsRNA poly:IC induced AA release through cPLA₂α activation, cPLA₂α-independent induction of COX-2, increase in PGE₂ production and an increase in expression of NO synthase (iNOS), which resulted dependent on cPLA₂ and COX-2, as demonstrated by pharmacological approaches and knockdown gene experiments. Thus, the TLR3 stimulation with dsRNA leads to a signaling cascade involving activation of cPLA₂α, induction of COX-2, with the subsequent production of PGE₂ which in turn promotes an enhanced iNOS expression. Remarkably, no role for sPLA₂ enzymes along this cascade of activation was found.

TLR4 - The stimulation of AA mobilization by TLR4 agonists has been extensively studied. The classic TLR4 agonist is LPS, a major component of Gram-negative bacterial cell walls. Although LPS on its own is a poor stimulus of AA release in primary cells of human and mice, it possesses a remarkable potency as a primer of the AA mobilization response. Thus LPS potentiates by several-fold the AA release response of a second stimulus that is added shortly after [52,53]. In

macrophage-like cell lines, however, LPS is able to elicit a robust AA mobilization on its own, although the response takes several hours to fully develop. This strong activating effect of LPS on macrophage cell lines has been extensively used as a model system for studies aiming at understanding cellular regulation of PLA₂ and AA mobilization for eicosanoid biosynthesis.

Well before the TLR4 receptor was identified, Balsinde et al. [11] demonstrated by the use of antisense oligonucleotide approaches that approx. 60-70% of [³H]AA released by murine macrophage-like P388D₁ cells primed with LPS and activated with PAF was under the control of a sPLA₂ enzyme. Further studies utilizing specific inhibitors [54] corroborated these findings and also provided evidence for the participation of cPLA₂α in the process, thus providing the first direct evidences that two distinct PLA₂ enzymes were involved in receptor-regulated AA mobilization reactions. A cross-talk between cPLA₂α and sPLA₂, where a prior activation of cPLA₂ was necessary for sPLA₂ to act was established [13]. Subsequent work demonstrated that the sPLA₂ involved in these processes was a novel group V enzyme, which had been discovered only two years before [55]. Activation by LPS/PAF induced sphingomyelin synthesis, with accumulation of ceramide and diacylglycerol, leading to activation of group V sPLA₂, probably via some sort of perturbation in the membrane [56].

In other series of studies, the delayed response of P388D₁ macrophage-like cells to LPS alone was investigated [57]. LPS stimulation activates cPLA₂α, which regulates sPLA₂-V expression and in turn mobilizes AA leading to PGE₂ production via COX-2, an enzyme whose induction was found to depend on the activity of group V sPLA₂ [57, 58]. These results were confirmed by Murakami et al. [12], who studied the effect of various sPLA₂ enzymes in AA metabolism when over-expressed in human embryonic kidney 293 (HEK 293) and Chinese hamster ovary (CHO-K1) stimulated with calcium ionophore (immediate response) or interleukin-1 (delayed response). In these studies it was demonstrated that cPLA₂α, group IIA sPLA₂ and group V sPLA₂ all mediate AA release, and that a synergism exists between cPLA₂α and the sPLA₂ enzymes in AA release; cPLA₂α was necessary for sPLA₂ but not the opposite [12].

Studies by confocal microscopy of P388D₁ cells stimulated with LPS concluded that sPLA₂-V is internalized in caveolin-enriched granules through the

perinuclear membrane, thus colocalizing with COX-2 and promoting AA release for subsequent production of prostaglandins [22]. Shirai et al. [59] also studied the localization of fusion proteins of cPLA₂α and sPLA₂-V in P388D₁ stimulated with PAF/LPS (primed immediate response) or LPS (delayed response). In the short-term stimulation, translocation of cPLA₂α to perinuclear/Golgi membranes was observed, whereas no significant changes in the localization of group V sPLA₂ were detected. In the long-term stimulation, both cPLA₂α and group V sPLA₂ translocated to intracellular membranes at 3 h, with release of AA being observed in a cPLA₂α-dependent manner.

In TLR4 knock-down experiments, Qi et al. [60] investigated the role of TLR4 in LPS-mediated stimulation in RAW 264.7 macrophages. In this system, activation of cPLA₂α for eicosanoid production was found to be regulated via TLR4 through MyD88 and TRIF adapter proteins, with the subsequent activation of MAPK and the PI3K/Akt cascade, although only the first one leads to phosphorylation of cPLA₂α. In human U937 macrophage-like cells and murine P388D₁ macrophages stimulated with LPS it has been described that the enhanced COX-2 expression and PGE₂ release is inhibited by the phosphatidate phosphohydrolase-1 inhibitors BEL and propranolol, and that diacylglycerol, product of phosphatidate phosphohydrolase-1, increases the inflammatory response of LPS, thus implicating phosphatidate phosphohydrolase-1, and more specifically its product, diacylglycerol, in the signaling pathway promoted by TLR4 stimulation [61]. Similar results have been obtained in murine macrophage RAW264.7 stimulated with the TLR4 agonist Kdo₂-lipid A, where activation of cPLA₂α is dependent on phosphatidate phosphohydrolase-1, which in turn activates protein kinase C through diacylglycerol production. However, neither phosphatidate phosphohydrolase-1 nor protein kinase C appear to be involved in the synergistic response promoted by TLR4 stimulation together with ATP (sustained-Ca²⁺ influx) [62].

TLR 7 and 8 - One study has been reported in human polymorphonuclear leukocytes stimulated by the synthetic agonist of TLR7 and 8 imidazoquinoline resiquimod (R-848) [63]. Priming cells to further stimulation with fMLP promotes cPLA₂α phosphorylation and 5-LO translocation, with the subsequent enhancement of AA release, biosynthesis of

PAF and leukotriene and increase of COX-2 expression. This study shows the ability of ssRNA to promote synthesis of lipid mediators through the TLR8 pathway.

TLR9 - TLR9 has been also implicated in AA release in macrophage-like cells RAW264.7 [64]. In this system, stimulation of TLR9 with CpG (a compound that is similar to bacterial DNA) leads to activation of cPLA₂α and subsequent AA release, in a process that is dependent on p38 and Akt pathways. In addition, cPLA₂α is crucial for enhanced expression of iNOS under TLR9 stimulation. Furthermore, the same group demonstrated in the same system that activation of cPLA₂α through TLR9 agonist promoted induction and JNK-mediated release of monocyte chemoattractant protein MCP-1 [65]. Importantly, AA release in TLR-mediated stimulation was found to be independent on sPLA₂ enzymes, as judged by the use of the cell-permeable inhibitor scalaradial.

To finish this section, two groups have comparatively studied the release of AA with multiple agonists for TLRs (TLR1 to 9). Buczynski et al. [66] characterized the eicosanoid profiles produced after activation of RAW264.7 macrophage-like cells by a variety of TLR agonists, but no striking differences were appreciated among the various agonists used. Ruipérez et al. [67] utilized P388D₁ and RAW264.7 macrophage-like cells to study the cross-talk between cPLA₂α and group V sPLA₂ in the release of AA under stimulation with agonists of TLR1 to 9. In this study it was found that all TLR agonists but TLR5 and TLR9 were able to induce AA mobilization by a mechanism involving both cPLA₂α and sPLA₂-V. The latter enzyme was reported to regulate phosphorylation of the former via ERK1/2.

5. AA mobilization in response to non-TLR agonists

Although much of the recent work on AA mobilization focuses mainly on stimulation via TLR, there is also significant data on the stimulation of AA mobilization via non-TLR receptors of the innate immunity.

As early as 1982, the release of AA in response to IgE complexes was demonstrated in mouse peritoneal macrophages [68]. With the establishment of gene knockdown and cloning technologies, the mechanisms

underlying this phenomenon have been characterized with detail at a molecular level. Fujishima et al. [14] sensitized bone marrow-derived mast cells (BMMC) from cPLA₂α^{+/+} and cPLA₂α^{-/-} mice with monoclonal mouse IgE anti-trinitrophenyl (TNP) ascites and then stimulated them with TNP-BSA in order to mimic a FcεRI-dependent activation. Under these experimental conditions they failed to observe detectable production of PGD₂ and LTC₄ in cPLA₂α^{-/-} mice, but robust generation of the two eicosanoids was found in cPLA₂α^{+/+} mice, demonstrating the essential role of cPLA₂α for the immediate production of eicosanoids via engagement of FcεRI. Work by the same group [69] also demonstrated that group V sPLA₂ amplifies the response of cPLA₂α, inducing a FcεRI-dependent COX-2 production and delaying the production of PGD₂, but not of LTC₄, in mouse BMMC.

The classical model for AA mobilization studies in the human neutrophil is via activation of the fMLP receptor, which interacts with f-Met-Leu-Phe, a bacterial chemotactin tripeptide. Stimulation of neutrophils with fMLP induces phosphorylation of cPLA₂α and AA release [70]. Interestingly, the phosphorylation of the enzyme was MAPK-independent, but AA release was inhibited by inhibitors of p38 MAPK and ERK, suggesting that these proteins play a role downstream cPLA₂α activation, perhaps by affecting the translocation of the enzyme where its substrate is located, or by reducing the increase in the intracellular levels of Ca²⁺ [70]. Two recent studies from the Rubín laboratory described in detail the importance of sPLA₂ in the human neutrophil response to agonists of the fMLP receptor. In the first paper [71] a central role in governing the AA release was attributed to cPLA₂α and an accessory secondary role was found for an unidentified sPLA₂ enzyme, and the suggestion was made that such sPLA₂ activity was somehow regulated by cPLA₂α. In a second study [72] the authors observed that production of leukotriene B₄ by fMLP-stimulated neutrophils was insensitive to sPLA₂ inhibitors, suggesting that production of this particular eicosanoid depends only on cPLA₂α activation.

6. The AA mobilization response to zymosan

For years, zymosan has constituted the classical stimulus for studies of AA mobilization in immunoinflammatory cells. Consequently, a wealth of data has accumulated on the role of PLA₂-mediated lipid

pathways in response to this agonist. Zymosan is a preparation of yeast cell walls consisting of protein-carbohydrate complexes, mainly formed by β-glucan and mannan. Zymosan has the ability to bind to different receptors in the macrophage surface depending on whether the particles are opsonized or not. Opsonized zymosan binds mainly to FcR and CR3, and although CR3 has also the capacity of binding nonopsonized zymosan by different sites, it has been reported not to induce AA release in murine peritoneal macrophages [73]. On the other hand, unopsonized zymosan binds preferentially to dectin-1 and, to a lesser extent, TLR2/TLR6.

Some three decades ago the release of AA and the production of prostaglandins and leukotrienes in murine peritoneal macrophages stimulated with unopsonized zymosan was demonstrated [74-76]. Dissection of the lipid pathways involved indicated a preeminent, if not exclusive, role for a PLA₂-like activity in effecting the AA release [77-79]. Such a PLA₂ activity was identified to correspond to that of cPLA₂α, and its cellular regulation by Ca²⁺ transients and phosphorylation was established [80, 81].

At that time the different PLA₂s present in cells and the receptors responsible for the recognition of zymosan were poorly characterized. With the cloning, characterization and better understanding of the function of the different PLA₂ groups, it was possible to study of stimulation mediated by zymosan in a much more detailed way. By using mice lacking cPLA₂α by genetic ablation, Gijón et al. [21] unambiguously demonstrated that this enzyme is essential for the AA release and eicosanoid production in response to unopsonized zymosan. Phosphorylation of cPLA₂α on Ser 505 in response to zymosan was found to be mediated by ERK and p38 MAPK, although the molecular significance of such a phosphorylation reaction still remains poorly understood [82]. Subsequently it was shown that in addition to translocating to perinuclear membranes, cPLA₂α also translocates to the phagosome during the phagocytosis of particles of unopsonized zymosan in mouse peritoneal macrophages [83]. Utilizing opsonized zymosan particles, Casas et al. [84] demonstrated in human monocyte-derived macrophages that translocation was regulated by the activation of JNK, which is responsible for the phosphorylation of cPLA₂α on Ser 505. In this study no translocation of other PLA₂ enzymes present in the cells to the phagosome could be observed [84].

With regard to the involvement of sPLA₂ family members in the amplification of cPLA₂α signaling, Satake et al. [85] generated mice lacking group V sPLA₂ and observed that peritoneal murine macrophages from these mice produced lower quantities of leukotriene C₄ and prostaglandin E₂ in response to zymosan compared to cells from wild-type mice. Following this observation, the same group [86] showed in peritoneal murine macrophages that group V sPLA₂ translocates to the phagosome during the phagocytosis of unopsonized zymosan particles. Staining of LTC₄ during phagocytosis demonstrated that this leukotriene was synthesized at the phagosome itself. Furthermore, peritoneal macrophages from group V sPLA₂-null mice presented a lower phagocytosis of zymosan particles. The suggestion was made that recruitment of sPLA₂ to the phagosome is induced in order to amplify the signal of the cPLA₂α already present in the phagosome, where both enzymes co-localize.

Suram et al. [48] observed that the AA release induced incubating mouse peritoneal macrophages with unopsonized zymosan is blocked by a highly purified preparation of soluble β-(1,3)-glucan phosphate. It was demonstrated in RAW 264.7 macrophages overexpressing dectin-1 or SIGIRR, a homologous receptor to DC-SIGN, that the receptor implicated in the activation of cPLA₂α and release of AA is dectin-1. In addition, zymosan induced the expression of COX-2 and the increase in the production of PGD₂ only in cells overexpressing dectin-1. Similarly, in human monocyte-derived dendritic cells it has been shown that unopsonized zymosan binds dectin-1 and DC-SIGN, and induces phosphorylation of Syk, activation of cPLA₂α and the subsequent mobilization of AA and COX-2 expression [87].

REFERENCES

- [1] Funk CD. Prostaglandins and leukotriens: advances in eicosanoid biology. *Science* 2001; 294: 1871-1875.
- [2] Burke JE, Dennis EA. Phospholipase A₂ biochemistry. *Cardiovasc Drugs Ther* 2009; 23:49–59.
- [3] Schaloske RH, Dennis EH. The phospholipase A₂ superfamily and its group numbering system. *Biochim Biophys Acta* 2006; 1761: 1246–1259.
- [4] Six DA, Dennis EA. The expanding superfamily of phospholipase A₂ enzymes: classification and characterization. *Biochim Biophys Acta* 2000; 1488:1-19.
- [5] Balsinde J, Winstead MV, Dennis EA. Phospholipase A₂ regulation of arachidonic acid mobilization. *FEBS Lett* 2002; 531: 2-6.
- [6] Balboa MA, Balsinde J. Oxidative stress and arachidonic acid mobilization. *Biochim. Biophys. Acta* 2006; 1761: 385-391.
- [7] Kudo I, Murakami M. Phospholipase A₂ enzymes. *Prostaglandins Other Lipid Mediat* 2002; 68-69: 3-58.
- [8] Leslie CC. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A₂. *Prostaglandins Leukot Essent Fatty Acids* 2004; 70: 373-376.
- [9] Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A₂ family. *Prog Lipid Res* 2006; 45: 487-510.
- [10] Kita Y, Ohto T, Uozumi N, Shimizu T. Biochemical properties and pathophysiological roles of cytosolic phospholipase A₂s. *Biochim Biophys Acta* 2006; 1761: 1317-1322.
- [11] Balsinde J, Barbour SE, Bianco ID, Dennis EA. Arachidonic acid in P388D₁ macrophages is controlled by two distinct Ca²⁺-dependent phospholipase A₂ enzymes. *Proc Natl Acad Sci* 1994; 91: 11060-11064.

- [12] Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tischfield JA, et al. The functions of five distinct mammalian phospholipase A₂s in regulating arachidonic acid release. *J Biol Chem* 1998; 273: 14411-14423.
- [13] Balsinde J, Balboa MA, Dennis EA. Functional coupling between secretory phospholipase A₂ and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A₂. *Proc Natl Acad Sci* 1998; 95: 7951-7956.
- [14] Fujishima H, Sanchez Mejia RO, Bingham III CO, Lam BK, Sapirstein A, Bonventre JV, Austen KF, Arm, JP. Cytosolic phospholipase A₂ is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. *Proc Natl Acad Sci USA* 1999; 96: 4803-4807.
- [15] Han WK, Sapirstein A, Hung CC, Alessandrini A, Bonventre JV. Cross-talk between cytosolic phospholipase A₂ α (cPLA₂ α) and secretory phospholipase A₂ (sPLA₂) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA₂ regulates cPLA₂ α activity that is responsible for the arachidonic acid release. *J Biol Chem* 2003; 278: 24153-24163.
- [16] Balsinde J, Dennis EA. Function and inhibition of intracellular calcium-independent phospholipase A₂. *J. Biol. Chem.* 1997; 272: 16069-16072.
- [17] Winstead MV, Balsinde J, Dennis EA. Calcium-independent phospholipase A₂. Structure and function. *Biochim. Biophys. Acta* 2000; 1488: 28-39.
- [18] Balsinde J, Pérez R, Balboa, MA. Calcium-independent phospholipase A₂ and apoptosis. *Biochim. Biophys. Acta* 2006; 1761: 1344-1350.
- [19] Balboa MA, Balsinde J, Dennis EA. Phosphorylation of cytosolic group IV phospholipase A₂ is necessary but not sufficient for arachidonic acid release in P388D₁ macrophages. *Biochem Biophys Res Commun* 2000; 267: 145-148.
- [20] Pérez R, Balboa MA, Balsinde J. Involvement of group VIA calcium-independent phospholipase A₂ in macrophage engulfment of hydrogen peroxide-treated U937 cells. *J Immunol* 2006; 176: 2555-2561.
- [21] Gijón MA, Spencer DM, Siddiqi AR, Bonventre JV, Leslie CC. Cytosolic phospholipase A₂ is required for macrophage arachidonic acid release by agonists that do not mobilize calcium. Novel role of mitogen-activated protein kinases pathways in cytosolic phospholipase A₂ regulation. *J Biol Chem* 2000; 275: 20146-20156.
- [22] Balboa MA, Shirai Y, Gaietta G, Ellisman MH, Balsinde J, Dennis EA. Localization of Group V phospholipase A₂ in caveolin-enriched granules in activated P388D₁ macrophage-like cells. *J Biol Chem* 2003; 278: 48059-48065.
- [23] Murakami M, Koduri RS, Enomoto A, Shimbara S, Seki M, Yoshihara K, Singer A, Valentin E, Ghomashchi F, Lambeau G, Gelb MH, Kudo I. Distinct arachidonate-releasing functions of mammalian secreted phospholipase A₂s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparin sulfate shuttling and external plasma membrane mechanisms. *J Biol Chem* 2001; 276: 10083-10096.
- [24] Mounier C, Ghomashchi F, Lindsay MR, James S, Singer AG, Parton RG, Gelb MH. Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A₂ occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A₂ α . *J Biol Chem* 2004; 279: 25024-25038.
- [25] Ni Z, Okeley NM, Smart BP, Gelb MH. Intracellular actions of group IIA secreted phospholipase A₂ and group IVA cytosolic phospholipase A₂ contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells. *J Biol Chem* 2006; 281: 16245-16255.
- [26] Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 2006; 124: 783-801.
- [27] Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the *Drosophila* Toll protein signals activation of adaptive immunity. *Nature* 1997; 388: 394-397.

- [28] Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to *Drosophila* Toll. *Proc Natl Acad Sci USA* 1998; 95: 588-593.
- [29] Takeuchi O, Kawai T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA, Takeda K, Akira S. TLR6: a novel member of an expanding Toll-like receptor family. *Gene* 1999; 231: 59-65.
- [30] Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. *Eur Cytokine Netw* 2000; 11: 362-371.
- [31] Chuang T-H, Ulevitch TJ. Cloning and characterization of a sub-family of human Toll-like receptors: hTLR7, hTLR8 and hTLR9. *Eur Cytokine Netw* 2000; 11: 372-378.
- [32] Chuang T-H, Ulevitch TJ. Identification of hTLR10: a novel human toll-like receptor preferentially expressed in immune cells. *Biochim Biophys Acta* 2001; 1518: 157-161.
- [33] Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe C. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. *Annu Rev Immunol* 2006; 24: 353-389.
- [34] Takeda K, Kaisho T, Akira S. Toll-like receptors. *Annu Rev Immunol* 2003; 21: 335-376.
- [35] Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A. The evolution of vertebrate Toll-like receptors. *Proc Natl Acad Sci USA* 2005; 102: 9577-9582.
- [36] Kawai T, Akira S. Innate immune recognition of viral infection. *Nat Immunol* 2006; 7: 131-137.
- [37] Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding-protein. *Science* 1990; 249: 1431-1433.
- [38] Stahl PD, Rodman JS, Miller MJ, Schlesinger PH. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. *Proc Natl Acad Sci USA* 1978; 75: 1399-1403.
- [39] Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S. Dectin-1 is a major beta-glucan receptor on macrophages. *J Exp Med* 2002; 196: 407-412.
- [40] Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor GC. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. *Cell* 2000; 100: 575-585.
- [41] Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. *Curr Opin Immunol* 2002; 14: 123-128.
- [42] Snyderman R and Goetzl EJ. Molecular and cellular mechanisms of leukocyte chemotaxis. *Science* 1981; 213: 830-837.
- [43] Ting J P-Y, Kastner DL, Hoffman HM. CATERPILLERS, pyrin and hereditary immunological disorders. *Nat Rev Immunol* 2006; 6: 183-195.
- [44] Nakhaei P, Genin P, Civas A, Hiscott J. RIG-I-like receptors: Sensing and responding to RNA virus infection. *Semin Immunol* 2009; 21: 215-222.
- [45] Hogg N. The leukocyte integrins. *Immunol Today* 1989; 10: 111-114.
- [46] Daeron M. Fc receptor biology. *Annu Rev Immunol* 1997; 15: 203-234.
- [47] Le Cabec V, Carreno S, Moisand A, Bordier C, Maridonneau-Parini I. Complement receptor 3 (CD18/CD11c) mediates type I and type II phagocytosis during nonopsonic and opsonic phagocytosis, respectively. *J Immunol* 2002; 169: 2003-2009.

- [48] Suram S, Brown GD, Ghosh M, Gordon S, Loper R, Taylor PR, et al. Regulation of cytosolic phospholipase A₂ activation and cyclooxygenase 2 expression in macrophages by the β -glucan receptor. *J Biol Chem* 2006; 281: 5506-5514.
- [49] Kikawada E, Bonventre JV, Arm JP. Group V secretory PLA₂ regulates TLR2-dependent eicosanoid generation in mouse cells through amplification of ERK and cPLA₂ α activation. *Blood* 2007; 110: 561-567.
- [50] Noor S, Goldfine H, Tucker DE, Suram S, Lenz LL, Akira S, et al. Activation of cytosolic phospholipase A₂ α in resident peritoneal macrophages by *Listeria monocytogenes* involves listeriolysin O and TLR2. *J Biol Chem* 2008; 283: 4744-4755.
- [51] Pindado J, Balsinde J, Balboa MA. TLR3-dependent induction of nitric oxide synthase in RAW264.7 macrophage-like cells via a cytosolic phospholipase A₂/cyclooxygenase-2 pathway. *J Immunol* 2007; 179: 4821-4828.
- [52] Aderem AA, Cohen DS, Wright SD, Cohn ZA. Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. *J Exp Med* 1986; 164: 165-179.
- [53] Aderem AA, Cohn ZA. Calcium ionophore synergizes with bacterial lipopolysaccharides in activating macrophage arachidonic acid metabolism. *J Exp Med* 1988; 167: 623-631.
- [54] Balsinde J, Dennis EA. Distinct roles in signal transduction for each of the phospholipase A₂ enzymes present in P388D₁ macrophages. *J Biol Chem* 1996; 271: 6758-6765.
- [55] Balboa MA, Balsinde J, Winstead MV, Tischfield JA, Dennis EA. Novel Group V phospholipase A₂ involved in arachidonic acid mobilization in murine P388D₁ macrophages. *J Biol Chem* 1996; 271: 32381-32384.
- [56] Balsinde J, Balboa MA, Dennis EA. Inflammatory activation of arachidonic acid signaling in murine P388D₁ macrophages via sphingomyelin synthesis. *J Biol Chem* 1997; 272: 20373-20377.
- [57] Shinohara H, Balboa MA, Johnson CA, Balsinde J, Dennis EA. J. Biol. Chem. Regulation of delayed prostaglandin production in activated P388D₁ macrophages by Group IV cytosolic and Group V secretory phospholipase A₂s. *J Biol Chem* 1999; 274: 12263-12268.
- [58] Balsinde J, Shinohara H, Lefkowitz LJ, Johnson CA, Balboa MA, Dennis EA. Group V phospholipase A₂-dependent induction of cyclooxygenase-2 in macrophages. *J Biol Chem* 1999; 274: 25967-25970.
- [59] Shirai Y, Balsinde J, Dennis EA. Localization and functional interrelationships among cytosolic Group V, and Ca²⁺-independent Group VI phospholipase A₂s in P388D₁ macrophages using GFP/RFP constructs. *Biochim Biophys Acta* 2005; 1735: 119-129.
- [60] Qi H-Y, Shelhamer JH. Toll-like receptor 4 signaling regulates cytosolic phospholipase A₂ activation and lipid generation in lipopolysaccharide-stimulated macrophages. *J Biol Chem* 2005; 280: 38969-38975.
- [61] Grkovich A, Johnson CA, Buczynski MW, Dennis EA. Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. *J Biol Chem* 2006; 281: 32978-32987.
- [62] Grkovich A, Armando A, Quehenberger O, Dennis EA. TLR-4 mediated group IVA phospholipase A₂ activation is phosphatidic acid phosphohydrolase 1 and protein kinase C dependent. *Biochim Biophys Acta* 2009; 1791: 975-982.
- [63] Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P. the Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B₄, prostaglandin E₂ and platelet-activating factor biosynthesis. *FASEB J* 2007; 21: 1575-1585.
- [64] Lee S-H, Lee J-G, Kim J-R, Baek S-H. Toll-like receptor 9-mediated cytosolic phospholipase A₂ activation regulates expression of inducible nitric oxide synthase. *Biochem Biophys Res Commun* 2007; 364: 996-1001.

- [65] Lee J-G, Lee S-H, Park D-W, Lee S-H, Yoon H-S, Chin B-R, et al. Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A₂-ROS signaling. *Cell Signal* 2008; 20: 105-111.
- [66] Buczynski MW, Stephens DL, Bowers-Gentry RC, Grkovich A, Deems RA, Dennis EA. TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells. *J Biol Chem* 2007; 282: 22834-22847.
- [67] Ruipérez V, Astudillo AM, Balboa MA, Balsinde J. Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by Group IVA and Group V phospholipase A₂s. *J Immunol* 2009; 182: 3877-3883.
- [68] Rouzer CA, Scott WA, Hamill AL, Liu F-T, Katz DH, Cohn ZA. IgE immune complexes stimulate arachidonic acid release by mouse peritoneal macrophages. *Proc Natl Acad Sci USA* 1982; 79: 5656-5660.
- [69] Diaz BL, Satake Y, Kikawada E, Balestrieri B, Arm JP. Group V secretory phospholipase A₂ amplifies the induction of cyclooxygenase 2 and delayed prostaglandin D₂ generation in mouse bone marrow culture-derived mast cells in a strain-dependent manner. *Biochim Biophys Acta* 2006; 1761: 1489-1497.
- [70] Syrbu SI, Waterman WH, Molski TFP, Nagarkatti D, Hajjar J-J, Sha'afi RI. Phosphorylation of cytosolic phospholipase A₂ and the release of arachidonic acid in human neutrophils. *J Immunol* 1999; 162: 2334-2340.
- [71] Marshall J, Krump E, Lindsay T, Downey G, Ford DA, Zhu P, Walker P, Rubin B. Involvement of cytosolic phospholipase A₂ and secretory phospholipase A₂ in arachidonic acid release from human neutrophils. *J Immunol* 2000; 164: 2084-2091.
- [72] Degousee N, Ghomashchi F, Stefanski E, Singer A, Smart BP, Borregaard N, Reithmeier R, Lindsay TF, Lichtenberger C, Reinisch W, Lambeau G, Arm J, Tischfield J, Gelb MH, Rubin BB. Groups IV, V, and X phospholipases A₂s in human neutrophils. Role in eicosanoid production and Gram-negative bacterial phospholipid hydrolysis. *J Biol Chem* 2002; 277: 5061-5073.
- [73] Aderem A, Wright SD, Silverstein SC, Cohn ZA. Ligated complement receptors do not activate the arachidonic acid cascade in resident peritoneal macrophages. *J Exp Med* 1985; 161: 617-622.
- [74] Bonney RJ, Wightman PD, Davies P, Sadowski SJ, Kuehl FA Jr, Humes JL. Regulation of prostaglandin synthesis and of the selective release of lysosomal hydrolases by mouse peritoneal macrophages. *Biochem J* 1978; 176: 433-442.
- [75] Scott W, Zrike JM, Hamill AL, Kempe J, Cohn ZA. Regulation of arachidonic acid metabolites in macrophages. *J Exp Med* 1980; 152: 324-225.
- [76] Rouzer CA, Scott WA, Cohn ZA, Blackburn P, Manning JM. Mouse peritoneal macrophages release leukotriene C in response to phagocytic stimulus. *Proc Natl Acad Sci USA* 1980; 77: 4928-4932.
- [77] Wightman PD, Dahlgren ME, Davies P, Bonney RJ. The selective release of phospholipase A₂ by resident mouse peritoneal macrophages. *Biochem J* 1981; 200: 441-444.
- [78] Emilsson A, Sundler R. Differential activation of phosphatidylinositol deacylation and a pathway via diphosphoinositide in macrophages responding to zymosan and inophore A23187. *J Biol Chem* 1984; 259: 3111-3116.
- [79] Balsinde J, Fernández B, Solís-Herruzo JA, Diez E. Pathways for arachidonic acid mobilization in zymosan-stimulated mouse peritoneal macrophages. *Biochim Biophys Acta* 1992; 1136: 75-82.
- [80] Qiu A-H, Leslie CC. Protein kinase C-dependent and -independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A₂. *J Biol Chem* 1994; 269: 19480-19487.

- [81] Balsinde J, Fernández B, Diez E. Regulation of arachidonic acid release in mouse peritoneal macrophages. The role of extracellular calcium and protein kinase C. *J Immunol* 1990; 144: 4298-4304.
- [82] Pérez-Chacón G, Astudillo AM, Balgoma D, Balboa MA, Balsinde J. Control of free arachidonic acid levels by phospholipases A₂ and lysophospholipid acyltransferases. *Biochim Biophys Acta* 2009; 1791: 1103-1113.
- [83] Girotti M, Evans JH, Burke D, Leslie CC. Cytosolic phospholipase A₂ translocates to forming phagosomes during phagocytosis of zymosan in macrophages. *J Biol Chem* 2004; 279: 19113-19121.
- [84] Casas J, Meana C, Esquinas E, Valdearcos M, Pindado J, Balsinde J, Balboa MA. Requirement of JNK-mediated phosphorylation for translocation of group IVA phospholipase A₂ to phagosomes in human macrophages. *J Immunol* 2009; 183: 2767-2774.
- [85] Satake Y, Diaz BL, Balestrieri B, Lam BK, Kanaoka Y, Grusby MJ, Arm JP. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by target gene disruption. *J Biol Chem* 2004; 279: 16488-16494.
- [86] Balestrieri B, Hsu VW, Gilbert H, Leslie CC, Han WK, Bonventre JV, Arm JP. Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis. *J Biol Chem* 2006; 281: 6691-6698.
- [87] Valera I, Fernández N, Trinidad AG, Alonso S, Brown GD, Alonso A, Crespo MS. Costimulation of dectin-1 and CD-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells. *J Immunol* 2008; 180: 5727-5736.




Figure 1. Ribbon diagram of cPLA₂α. The C2 domain on the left mediates interaction of the enzyme with membranes via binding of two Ca²⁺ atoms. The active site Ser 228 on the catalytic domain is highlighted, as is the phosphorylation site Ser 505.




Figure 3. The Toll-like receptor family and its ligands.